Brawn Biotech

Who are the top shareholders of the Brawn Biotech?

The top shareholders of Brawn Biotech are primarily promoters, with Brij Raj Gupta holding the largest stake at 16.69%. Individual investors own 33.17% of the shares, while the highest public shareholder is Daksha Kotak at 1.24%.

The top shareholders of Brawn Biotech primarily include the promoters, with Brij Raj Gupta holding the largest individual stake at 16.69%. Additionally, individual investors collectively own 33.17% of the shares. The company has no pledged promoter holdings, and there are no foreign institutional investors (FIIs) involved. The highest public shareholder is Daksha Kotak, who holds 1.24%. Overall, the majority of the shares are held by the promoters.

Who are in the management team of Brawn Biotech?

As of March 2021, the management team of Brawn Biotech consists of B R Gupta (Chairman & Managing Director), Brij Bala Gupta (Director), Subhash Chander (Independent Director), Kanta Takkar (Independent Director), and Priyanka Sharma (Company Secretary), all receiving a remuneration of Rs. 0.

As of March 2021, the management team of Brawn Biotech includes:<BR><BR>1. B R Gupta - Chairman & Managing Director<BR>2. Brij Bala Gupta - Director<BR>3. Subhash Chander - Independent Director<BR>4. Kanta Takkar - Independent Director<BR>5. Priyanka Sharma - Company Secretary<BR><BR>All members of the management team have a remuneration of Rs. 0.

What does Brawn Biotech do?

Brawn Biotech Ltd is a micro-cap healthcare group in the Pharmaceuticals & Biotechnology sector, reporting net sales of 2 Cr and a net profit of 0 Cr for the quarter ending March 2025. The company, originally founded in 1985, has a market cap of Rs 5 Cr and operates from New Delhi.

Overview: <BR>Brawn Biotech Ltd is a fully integrated healthcare group operating in the Pharmaceuticals & Biotechnology industry, categorized as a Micro Cap company.<BR><BR>History: <BR>Brawn Biotech Ltd was originally incorporated as Brawn Pharmaceuticals Limited in November 1985. The company changed its name to Brawn Biotech Limited in November 2010. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 2 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 0 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: Rs 5 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: N/A <BR>Industry P/E: 27 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: -0.06 <BR>Return on Equity: -42.32% <BR>Price to Book: 1.17<BR><BR>Contact Details: <BR>Address: C-64 Lajpat Nagar-1 1st Floor, New Delhi, New Delhi: 110024 <BR>Email: solution@brawnpharma.com <BR>Website: http://www.brawnbiotech.com

Has Brawn Biotech declared dividend?

Brawn Biotech Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of September 12, 2018. However, the company has shown significant losses over various periods, resulting in a consistent dividend yield of 0% in recent times.

Brawn Biotech Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1<BR>- Ex-date: 12 Sep 18<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the 6 months period, the price return was -25.42%, the dividend return was 0%, resulting in a total return of -25.42%.<BR><BR>In the 1 year period, the price return was -37.33%, the dividend return was 0%, resulting in a total return of -37.33%.<BR><BR>In the 2 years period, the price return was 1.23%, the dividend return was 0%, resulting in a total return of 1.23%.<BR><BR>In the 3 years period, the price return was -13.68%, the dividend return was 0%, resulting in a total return of -13.68%.<BR><BR>In the 4 years period, the price return was -50.3%, the dividend return was 0%, resulting in a total return of -50.3%.<BR><BR>In the 5 years period, the price return was -40.15%, the dividend return was 0%, resulting in a total return of -40.15%.<BR><BR>Overall, while Brawn Biotech has declared a dividend, the total returns over various periods indicate significant losses, particularly in the longer term, suggesting challenges in the company's financial performance. The consistent dividend yield of 0% in recent periods further reflects a lack of ongoing dividend distributions.

Is Brawn Biotech overvalued or undervalued?

As of June 11, 2024, Brawn Biotech is considered risky and overvalued due to its negative PE ratio of -2.75, poor financial metrics compared to peers, and a year-to-date stock performance decline of -23.04%.

As of 11 June 2024, Brawn Biotech's valuation grade has moved from does not qualify to risky, indicating a significant change in its perceived financial health. The company appears to be overvalued given its negative PE ratio of -2.75, an EV to EBIT of -2.48, and a ROCE of -47.62%. These ratios highlight the company's struggles in generating profits and returns on capital.<BR><BR>In comparison to its peers, Brawn Biotech's financial metrics stand out unfavorably. For instance, MMTC has a PE ratio of 119.39, while PTC India boasts a much more attractive PE of 9.02, showcasing the stark contrast in valuation within the industry. Additionally, Brawn Biotech's recent stock performance has been poor, with a year-to-date return of -23.04% compared to the Sensex's positive return of 5.58%, reinforcing the notion that the company is overvalued in its current state.

What is the technical trend for Brawn Biotech?

As of June 3, 2025, Brawn Biotech's trend has shifted to bearish with moderate strength, driven by daily moving averages and Bollinger Bands, despite mixed signals from the MACD and KST, and a year-to-date return of -19.29% compared to the Sensex's 5.51% gain.

As of 3 June 2025, the technical trend for Brawn Biotech has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include the daily moving averages indicating a bearish trend, and both the weekly and monthly Bollinger Bands confirming a bearish outlook. The MACD shows a mildly bullish signal on the weekly timeframe but is bearish on the monthly, indicating mixed signals. The KST is also mildly bullish weekly but bearish monthly, adding to the overall bearish sentiment. The stock's performance has been weak, with a year-to-date return of -19.29%, contrasting with the Sensex's positive return of 5.51%.

Who are the peers of the Brawn Biotech?

Brawn Biotech's peers include Unjha Formul., Beryl Drugs, Cian Healthcare, Adline Chem Lab, Ortin Global, Vivanza Biosci., Ganga Pharma., Shyama Computro., and Fabino Enter. Unjha Formul. shows excellent management and the highest 1-year return at 23.34%, while Cian Healthcare has the lowest return at -81.16%.

Peers: The peers of Brawn Biotech are Unjha Formul., Beryl Drugs, Cian Healthcare, Adline Chem Lab, Ortin Global, Vivanza Biosci., Ganga Pharma., Shyama Computro., Fabino Enter.<BR><BR>Quality Snapshot: Excellent management risk is observed at Unjha Formul., while Below Average management risk is found at Beryl Drugs, Cian Healthcare, Ortin Global, Vivanza Biosci., Ganga Pharma., and Fabino Enter, and the rest have management risks that do not qualify. Growth is Below Average for Beryl Drugs, Cian Healthcare, Ortin Global, Vivanza Biosci., Ganga Pharma., and Fabino Enter, while Adline Chem Lab and Shyama Computro. do not qualify for growth. Capital Structure is Good at Unjha Formul., Average at Fabino Enter, and Below Average at Beryl Drugs, Cian Healthcare, Ortin Global, Vivanza Biosci., Ganga Pharma., and the rest.<BR><BR>Return Snapshot: Unjha Formul. has the highest 1-year return at 23.34%, while Cian Healthcare has the lowest at -81.16%, with Brawn Biotech's 1-year return at -19.73% being significantly better than Cian Healthcare's. Additionally, Beryl Drugs, Cian Healthcare, Ortin Global, Vivanza Biosci., Ganga Pharma., and Fabino Enter all have negative six-month returns.

How big is Brawn Biotech?

As of 23rd July, Brawn Biotech Ltd has a market capitalization of 5.00 Cr, with recent net sales of 0.36 Cr and a net profit of 0.21 Cr. Shareholder's funds are 5.07 Cr and total assets amount to 14.13 Cr as of March 2024.

As of 23rd July, Brawn Biotech Ltd has a market capitalization of 5.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Brawn Biotech reported Net Sales of 0.36 Cr and a Net Profit of 0.21 Cr. <BR><BR>The latest annual period for the balance sheet is March 2024, with Shareholder's Funds amounting to 5.07 Cr and Total Assets totaling 14.13 Cr.

Are Brawn Biotech latest results good or bad?

Brawn Biotech's latest results show a generally positive trend, with significant increases in operating profit, net sales, and earnings per share. However, the stock is rated as a 'Strong Sell' by MarketsMOJO, indicating potential concerns for investors.

Brawn Biotech's latest results indicate a mixed but generally positive performance. While the overall financial performance is described as flat, there are significant improvements in key metrics compared to the previous quarter. <BR><BR>The company achieved its highest operating profit in the last five quarters, reaching Rs 0.18 crore, and the profit before tax also peaked at Rs 0.15 crore. Furthermore, the profit after tax was recorded at Rs 0.24 crore, marking the highest level in the same period. The earnings per share (EPS) increased to Rs 0.80, reflecting enhanced profitability for shareholders.<BR><BR>Additionally, there was a remarkable growth in net sales and standalone net profit, with net sales increasing by 156.64% and net profit rising by 148.98% compared to the previous quarter. These trends suggest a potential stabilization and improvement in the company's financial health.<BR><BR>However, despite these positive indicators, the stock is currently rated as a 'Strong Sell' by MarketsMOJO, which may reflect concerns about future performance or market conditions. Overall, while there are positive trends in profitability, the mixed rating suggests caution for investors.

When is the next results date for Brawn Biotech?

Brawn Biotech will announce its results on 14 November 2025.

Brawn Biotech will declare its results on 14 November 2025.

How has been the historical performance of Brawn Biotech?

As of March 2023, Brawn Biotech reported net sales and total operating income of 0.48 crore, with a profit after tax of 0.19 crore and a PAT margin of 39.58%. The company has total assets and liabilities of 14.37 crore each, no debt, and stagnant cash flow, indicating limited operational activity and a need for revenue growth.

Answer:<BR>The historical performance of Brawn Biotech shows a modest financial position as of March 2023, with net sales reported at 0.48 crore and total operating income also at 0.48 crore. The company incurred total expenditure of 0.48 crore, resulting in an operating profit (PBDIT) of 0.24 crore after accounting for other income. The profit before tax stood at 0.22 crore, leading to a profit after tax of 0.19 crore, which translates to a PAT margin of 39.58%. The earnings per share (EPS) were recorded at 0.39, while the diluted EPS was slightly lower at 0.38. <BR><BR>In terms of assets and liabilities, Brawn Biotech's total assets as of March 2023 were 14.37 crore, with total liabilities at 14.37 crore, indicating a balanced sheet with no debt. The company's shareholder's funds were 6.31 crore, and the book value per share adjusted was 21.03. The cash flow results indicate that the company had no cash inflow or outflow from operating, investing, or financing activities, reflecting a stagnant cash position over the years. Overall, Brawn Biotech's financials suggest a company with limited operational activity and a need for growth in revenue generation. <BR><BR>Breakdown:<BR>Brawn Biotech's financial performance as of March 2023 reveals net sales of 0.48 crore, with total operating income matching this figure. The company faced total expenditures of 0.48 crore, leading to an operating profit of 0.24 crore, bolstered by other income. The profit before tax was 0.22 crore, resulting in a profit after tax of 0.19 crore, which corresponds to a PAT margin of 39.58%. The earnings per share were 0.39, while the diluted EPS was slightly lower at 0.38. On the balance sheet, total assets and liabilities were both at 14.37 crore, with shareholder's funds at 6.31 crore and a book value per share of 21.03. The cash flow statements indicate no activity in cash inflows or outflows, suggesting a lack of operational movement in the company's financial activities.

Should I buy, sell or hold Brawn Biotech Ltd?

Why is Brawn Biotech Ltd falling/rising?

As of 05-May, Brawn Biotech Ltd's stock price is stable at 20.80, but it has declined 9.37% over the past week, indicating negative investor sentiment and declining participation. Despite some long-term gains, the stock's year-to-date performance is down 3.30%, suggesting downward pressure on its price.

As of 05-May, Brawn Biotech Ltd's stock price is currently stable at 20.80, showing no change (0.00%). However, the stock has experienced a significant decline in performance over the past week, with a drop of 9.37%, while the benchmark Sensex has only increased by 0.17%. This underperformance is indicative of investor sentiment towards the stock.<BR><BR>In terms of trading activity, the stock has shown erratic trading patterns, having not traded on 3 out of the last 20 days. Additionally, there has been a notable decrease in investor participation, with the delivery volume on April 30 falling by 98.33% compared to the 5-day average. This decline in trading volume suggests a lack of interest among investors, which can contribute to downward pressure on the stock price.<BR><BR>Despite some positive indicators over longer periods, such as a 22.07% increase over the past year and a 28.87% increase over the past three years, the stock's year-to-date performance is down by 3.30%, contrasting with the Sensex's decline of 9.63%. The stock is currently trading higher than its 20-day, 50-day, 100-day, and 200-day moving averages, but lower than its 5-day moving average, indicating mixed signals regarding its short-term momentum.<BR><BR>Overall, the combination of recent poor performance, declining investor participation, and erratic trading behavior suggests that Brawn Biotech Ltd's stock is facing downward pressure, contributing to its current price stability at 20.80.

Which are the latest news on Brawn Biotech?